SEEKING OLDER ADULTS FOR A NEW MEMORY STUDY AT UC IRVINE
Lead researcher: S. Ahmad Sajjadi, MD, PhD, MRCP
Study Title: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of MTAU9937A in Patients with Prodromal to Mild Alzheimer’s Disease
Purpose of Study: To compare the safety and effectiveness of an investigational drug called MTAU9937A versus placebo in people with Mild Cognitive Impairment (MCI) or mild Alzheimer’s disease (AD).
Eligibility: Male and female participants ages 50-80 years old, who have been diagnosed with early Alzheimer’s Disease (mild cognitive impairment or mild AD), with evidence of amyloid pathology on a brain scan. All study subjects must have an informant/care partner who can attend required study visits and can provide accurate information about the subject’s cognitive and functional abilities.
Location: UCI Campus (UCI MIND Gottschalk Medical Plaza, ICTS in Hewitt Hall, Neuro Imaging Center), Newport Diagnostic Center
Time commitment: Screening Phase (up to 8 weeks). If you are eligible for the treatment phase (which includes a double blind treatment phase and an open label phase), you will receive placebo or MTAU9937 and have approximately 45 visits over the course of up to 169 weeks.
Anticipated benefits: You may or may not receive any benefit from being in this study. If you are in the group that receives the study drug, MTAU9937, and it proves to treat your condition better than placebo, you may benefit from participating in the study, but this cannot be guaranteed. The information collected from this study may increase knowledge regarding the treatment of Alzheimer’s disease and help people in the future.
Compensation: Participants are eligible to receive the following compensation in cash during the course of this study:
Double Blind Treatment phase of this study:
- $50 for each completed MRI scan; there are 4 MRI scans ($200 max).
- $100 for each completed PET scan; there are up to 4 PET scans ($400 max).
- $100 for each completed lumbar puncture; there are 3 optional lumbar punctures ($400 max).
- $25 for each clinic visit; there are approximately 21 clinic visits ($525 max).
Open Label Extension phase of this study:
- $50 for each completed MRI scan; there are 2 MRI scans ($100 max).
- $100 for each completed PET scan; there is 1 PET scan ($100 max).
- $100 for each completed lumbar puncture; there is 1 optional lumbar puncture ($100 max).
- $25 for each clinic visit; there are approximately 24 clinic visits ($600 max).
If you decide to withdraw from the study or are withdrawn by the research team, you will receive compensation for the visits and/or procedures that you have completed.
Reimbursement: You will not be reimbursed for any out of pocket expenses, such as parking or transportation fees.
Contact name, Department, Phone Number and Email:
Clinical Trials Research Inquiry Coordinator
Institute for Memory Impairments and Neurological Disorders (UCI MIND)
Alzheimer’s Disease Research Center (ADRC)
1100 Gottschalk Medical Plaza
Irvine, CA 92697-4285
UCI IRB Approved: 06-15-2018 | MOD# 24125 | HS# 2018-4292